Gensight Biologics SA
PAR:SIGHT
Gensight Biologics SA
Common Shares Outstanding
Gensight Biologics SA
Common Shares Outstanding Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Gensight Biologics SA
PAR:SIGHT
|
Common Shares Outstanding
€103.4m
|
CAGR 3-Years
31%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Common Shares Outstanding
€139.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Innate Pharma SA
PAR:IPH
|
Common Shares Outstanding
€80.9m
|
CAGR 3-Years
1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
4%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Common Shares Outstanding
€49.8m
|
CAGR 3-Years
3%
|
CAGR 5-Years
5%
|
CAGR 10-Years
8%
|
|
|
Inventiva SA
PAR:IVA
|
Common Shares Outstanding
€52.5m
|
CAGR 3-Years
11%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Common Shares Outstanding
€10m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
13%
|
|
Gensight Biologics SA
Glance View
GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).
See Also
What is Gensight Biologics SA's Common Shares Outstanding?
Common Shares Outstanding
103.4m
EUR
Based on the financial report for Jun 30, 2024, Gensight Biologics SA's Common Shares Outstanding amounts to 103.4m EUR.
What is Gensight Biologics SA's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 5Y
29%
Over the last year, the Common Shares Outstanding growth was 124%. The average annual Common Shares Outstanding growth rates for Gensight Biologics SA have been 31% over the past three years , 29% over the past five years .
You don't have any saved screeners yet